Vanda Pharmaceuticals (NASDAQ:VNDA) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note released on Sunday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald upped their price objective on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an overweight rating in a research note on Thursday, August 1st.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ:VNDA opened at $4.85 on Friday. Vanda Pharmaceuticals has a 1 year low of $3.30 and a 1 year high of $6.75. The company has a market capitalization of $282.26 million, a PE ratio of -60.63 and a beta of 0.77. The business has a fifty day moving average price of $5.34 and a two-hundred day moving average price of $5.14.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter. The company had revenue of $50.47 million for the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%. Sell-side analysts anticipate that Vanda Pharmaceuticals will post -0.49 earnings per share for the current year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VNDA. Price T Rowe Associates Inc. MD increased its stake in shares of Vanda Pharmaceuticals by 18.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 2,425 shares in the last quarter. Panagora Asset Management Inc. boosted its holdings in Vanda Pharmaceuticals by 4.3% in the 2nd quarter. Panagora Asset Management Inc. now owns 60,434 shares of the biopharmaceutical company’s stock worth $341,000 after buying an additional 2,509 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in Vanda Pharmaceuticals by 65.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,045 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 4,387 shares in the last quarter. Susquehanna Fundamental Investments LLC raised its holdings in Vanda Pharmaceuticals by 2.1% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 287,677 shares of the biopharmaceutical company’s stock valued at $1,625,000 after acquiring an additional 5,994 shares during the period. Finally, Meeder Asset Management Inc. purchased a new stake in shares of Vanda Pharmaceuticals during the second quarter worth $39,000. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.